Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endostar with Chemotherapy and EGFR-TKI in Resistant Lung Cancer
NCT02350361Phase 3Unknown
- Sponsor
- Peking University Third Hospital
- Start
- Jan 2014
- Primary completion
- Jul 2015
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of endostar in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Peking University Third Hospital. Primary endpoint: Objective Response Rate at 2 months. Status: unknown.
02
Drugs
endostar
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02350361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02350361.